Not Logged In

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.